StockData
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. (CCCC) stock

CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.48−0.05 (-2.17%)

Close on Nov 18, 2026Market cap $304.49MP/E –Yield –

C4 Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

C4 Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$85.39M. For fiscal 2025 it was -$99.30M. The highest annual figure on record is $54.27M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$99.30M–
FY2024Dec 31, 2024-$65.34M–
FY2023Dec 31, 2023-$108.55M–
FY2022Dec 31, 2022-$111.44M–
FY2021Dec 31, 2021-$88.24M–
FY2020Dec 31, 2020-$67.90M-225.1%
FY2019Dec 31, 2019$54.27M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.61M–
Q1 FY2026Mar 31, 2026-$30.01M–
Q4 FY2025Dec 31, 2025-$22.16M–
Q3 FY2025Sep 30, 2025-$31.62M–
Q2 FY2025Jun 30, 2025-$12.24M–
Q1 FY2025Mar 31, 2025-$33.29M–
Q4 FY2024Dec 31, 2024-$17.93M–
Q3 FY2024Sep 30, 2024-$24.12M–
Q2 FY2024Jun 30, 2024-$5.17M–
Q1 FY2024Mar 31, 2024-$18.12M–
Q4 FY2023Dec 31, 2023-$24.17M–
Q3 FY2023Sep 30, 2023-$31.31M–
Q2 FY2023Jun 30, 2023-$19.36M–
Q1 FY2023Mar 31, 2023-$33.71M–
Q4 FY2022Dec 31, 2022-$30.62M–
Q3 FY2022Sep 30, 2022-$31.33M–
Q2 FY2022Jun 30, 2022-$22.72M–
Q1 FY2022Mar 31, 2022-$26.77M–
Q4 FY2021Dec 31, 2021-$25.78M–
Q3 FY2021Sep 30, 2021-$18.36M–
Q2 FY2021Jun 30, 2021-$18.75M–
Q1 FY2021Mar 31, 2021-$25.36M–
Q4 FY2020Dec 31, 2020-$21.88M–
Q3 FY2020Sep 30, 2020-$14.68M–
Q2 FY2020Jun 30, 2020-$14.49M–
Q1 FY2020Mar 31, 2020-$16.85M–
Q4 FY2019Dec 31, 2019-$10.23M–

More C4 Therapeutics figures

See a number that looks wrong?